Related Experiment Video
Updated: Jun 3, 2026
06:50
A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases
Published on: May 29, 2020
Autoimmune polyglandular syndrome type 2 shows the same HLA class II pattern as type 1 diabetes
C Weinstock1, N Matheis, S Barkia
1German Red Cross Blood Service West, Hagen, Germany. c.weinstock@bsdwest.de
Tissue Antigens
|March 11, 2011
Summary
Autoimmune Polyglandular Syndrome type 2 (APS 2) shares common genetic links with type 1 diabetes (T1D), suggesting a similar immunogenetic basis. These findings highlight specific human leukocyte antigen (HLA) alleles and haplotypes associated with APS 2 and T1D.
Area of Science:
- Immunogenetics
- Endocrinology
- Human Leukocyte Antigen (HLA) complex
Background:
- Autoimmune Polyglandular Syndrome (APS) type 2 is characterized by the co-occurrence of multiple autoimmune endocrine diseases.
- Limited data exists regarding the specific genetic associations underlying APS type 2.
- Understanding these genetic factors is crucial for elucidating disease pathogenesis.
Purpose of the Study:
- To investigate the association of human leukocyte antigen (HLA) class II alleles (DRB1, DQA1, DQB1) with Autoimmune Polyglandular Syndrome type 2 (APS 2).
- To compare the genetic profiles of APS type 2 patients with those of type 1 diabetes (T1D) and autoimmune thyroid disease (AITD) patients.
- To identify susceptible and protective HLA haplotypes in APS type 2.
Main Methods:
- A controlled study involving 98 patients with APS type 2, 96 with T1D, and 92 with AITD.
- Genotyping for HLA class II loci DRB1, DQA1, and DQB1.
- Statistical analysis to compare allele and haplotype frequencies between patient groups and controls.
Main Results:
- Patients with APS type 2 exhibited significantly higher frequencies of HLA alleles DRB1*03, DRB1*04, DQA1*03, and DQB1*02 compared to controls.
- Conversely, APS type 2 patients showed lower frequencies of DRB1*15, DQA1*01, and DQB1*05.
- Identified susceptible haplotypes (e.g., DRB1*0301-DQA1*0501-DQB1*0201) and protective haplotypes (e.g., DRB1*1501-DQA1*0102-DQB1*0602).
- T1D patients shared similar susceptible and protective HLA alleles and haplotypes with APS type 2 patients.
- The association of specific HLA alleles with APS type 2 was independent of the presence of diabetes.
Conclusions:
- The findings suggest a shared immunogenetic mechanism between Autoimmune Polyglandular Syndrome type 2 and type 1 diabetes.
- The identified HLA associations provide insights into the genetic predisposition for APS type 2.
- The immunogenetic pathway for APS type 2 may differ from that of other autoimmune endocrine diseases.
Related Concept Videos
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...